Home Page - Slider
For Patients
To learn about your genetic testing options, please visit www.mytestingoptions.com
Integrated Genetics Highlights
LabCorp is pleased to offer the PreTRM Test for Risk Management by Sera Prognostics, a first-of-its-kind blood test validated to predict an individual woman’s risk for sPTB. Today, preterm birth is still the leading cause of infant mortality and morbidity in the US and worldwide. The PreTRM test is an innovative blood test that provides an accurate risk assessment for preterm birth, allowing for early intervention to help reduce the risk of preterm birth in the current pregnancy. To find out more about the PreTRM test, please visit www.PreTRM.com.
Now available - ten new panels in the VistaSeq® Hereditary Cancer portfolio. With each new panel focusing on the risk of specific hereditary cancer syndromes, physicians are enabled to select the panel that best meets the needs of each patient based on their personal or family history. Click here to view the press release.
Recently, the New York Stock Exchange welcomed officials and guests of the National Fragile X Foundation to raise awareness of Fragile X syndrome, the most common inherited cause of intellectual disability and autism. Click here to watch them ring the opening bell.
LabCorp is pleased to offer the PreTRM Test for Risk Management by Sera Prognostics, a first of its kind blood test validated to predict an individual woman’s risk for sPTB. Today, preterm birth is still the leading cause of infant mortality and morbidity in the US and worldwide. The PreTRM test is an innovative blood test that provides an accurate risk assessment for preterm birth, allowing for early intervention to help reduce the risk of preterm birth in the current pregnancy. To find out more about the PreTRM test, please visit www.PreTRM.com.
Integrated Genetics has long been a leader in screening for spinal muscular atrophy (SMA). We believe the American College of Obstetricians and Gynecologists' recent opinion validates our efforts, stating that, in addition to cystic fibrosis, carrier screening for SMA "should be offered to all women who are considering pregnancy or are currently pregnant." To read the statement, click here.
Integrated Genetics presented a number of key studies and advancements at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting in Phoenix, AZ March 21-25, 2017. Included were eleven (11) scientific abstracts and an exhibit theater that demonstrate our ongoing commitment and continued leadership in the molecular, medical, and fetal genetics spaces. Please click here to view the posters that were presented.
“With the addition of Sequenom, LabCorp is a market leader for non-invasive prenatal testing, women’s health and reproductive genetics,” said David P. King, chairman and chief executive officer of LabCorp. “This strategic acquisition also expands our reach both domestically and internationally and furthers our mission to improve health and improve lives around the globe.”
Analysis of over 7,400 mutations found in 142 different genes, associated with more than 114 different inherited diseases